MSB

6.00%

94.0¢

MESOBLAST LIMITED

Market Cap $1.073B Add to my watchlist

Healthcare Biotechnology

Mesoblast Limited is an Australia-based company, which is engaged in developing... Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. It has established commercial partnerships in Europe and China for certain Phase III assets.More

BlinkLab Limited (ASX: BB1) is a trailblazer in digital healthcare, leveraging AI and machine learning in mobile applications to revolutioniSe neurodevelopmental condition diagnosis like ASD and ADHD. Born from extensive research at Princeton University,...

Latest Threads

Tag

Subject

MSB

Pick Today's Price Range Low-High... Just for Fun

9 10 11

09:02

604

201K

09:02

Last post col69

604

201K

MSB

MESO Nasdaq update

90 91 92

09:01

5.4K

2.7M

09:01

Last post nippy

5.4K

2.7M

MSB

2024 Here we go again.

11 12 13

08:58

773

317K

08:58

Last post DocMcstuffins

773

317K

MSB

Ann: Mesoblast to File BLA for Ryoncil FDA Approval Next Week

2 3

02/07/24

142

50K

02/07/24

Last post gavint66

142

50K

MSB

banter and General Discussion

166 167 168

02/07/24

10K

3.0M

02/07/24

Last post Wilba32

10K

3.0M

MSB

Cell Therapy News/Articles

295 296 297

02/07/24

17K

6.7M

02/07/24

Last post quartear

17K

6.7M

MSB

Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA

17 18 19

02/07/24

1.0K

422K

02/07/24

Last post csrwin

1.0K

422K

MSB

here we comes

01/07/24

256

01/07/24

Last post Dylan_

256

See All Discussions

Timeline

Mesoblast to File BLA for Ryoncil FDA Approval Next Week
01 Jul 15:00	Share

Mesoblast Corporate Presentation at Investor Conference
03 Jun 09:27	Share

Corporate Presentation
03 Jun 09:22	Share

Appendix 3Y for Eric Rose
10 May 09:22	Share

Appendix 3Y for Eric Rose
03 May 09:49	Share

Change in substantial holding
02 May 09:49	Share

Quarterly Activities/Appendix 4C Cash Flow Report
30 Apr 09:59	Share

Mesoblast Chair Transition
30 Apr 09:47	Share

Appendix 3Y for Jane Bell
16 Apr 09:18	Share

Application for quotation of securities - MSB
16 Apr 09:15	Share

Notification regarding unquoted securities - MSB
16 Apr 09:06	Share

Notification of cessation of securities - MSB
15 Apr 17:02	Share

Change in substantial holding
09 Apr 09:23	Share

Change in substantial holding
02 Apr 09:53	Share

FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
26 Mar 13:05	Share

Pause in Trading
26 Mar 09:52	Share

Cleansing Notice
26 Mar 09:48	Share

Application for quotation of securities - MSB
22 Mar 16:32	Share

Change in substantial holding
20 Mar 09:46	Share

Proposed issue of securities - MSB
20 Mar 09:37	Share

Cleansing Notice
19 Mar 08:45	Share

Appendix 2A
18 Mar 12:09	Share

Proposed issue of securities - MSB
14 Mar 16:55	Share

Mesoblast Completes Placement and Entitlement Offer
14 Mar 09:54	Share

FDA Supports Accelerated Approval Pathway for Heart Failure
11 Mar 09:57	Share

MSB Q2 Financial Results and Operational Highlights
29 Feb 08:54	Share

Half Year Financial Results Presentation
29 Feb 08:49	Share

Half Year Report and Accounts (including Appendix 4D)
29 Feb 08:46	Share

Mesoblast 2024 Half Year Financial Results Webcast
26 Feb 17:00	Share

FDA Grants Orphan Drug Designation for Revascor
15 Feb 10:46	Share

View More

(20min delay)
Last 94.0¢		Change -0.060(6.00%)		Mkt cap ! $1.073B

Open	High	Low	Value	Volume
99.0¢	99.5¢	93.5¢	$5.643M	5.894M

Buyers (Bids)

No.	Vol.	Price($)
14	72266	93.5¢

Sellers (Offers)

Price($)	Vol.	No.
94.5¢	20000	1

View Market Depth

No.	Vol.	Price($)
1	973	0.975
1	1005	0.950
2	1063	0.945
5	22792	0.940
8	37111	0.935

Price($)	Vol.	No.
0.930	790	1
0.940	5630	4
0.945	20000	1
0.950	67722	2
0.955	60000	2

Last trade - 16.10pm 02/07/2024 (20 minute delay)


Last 94.0¢		Change -0.060 ( 5.84 %)
Open	High	Low	Volume
99.0¢	99.0¢	93.5¢	1629472
Last updated 15.59pm 02/07/2024 ?

MSB (ASX) Chart

MESOBLAST LIMITED

Latest Threads

Ark Mines defines significant exploration target at Sandy Mitchell rare earths

Timeline

Featured News

Latest Videos

Mesoblast (ASX:MSB) flags strengthened heart function in latest trial results

28 Feb 2023 10:07 (AEDT)

Latest Articles

Mesoblast (ASX:MSB) completes $97M funding round heading into Q2

Mesoblast (ASX:MSB) has completed its pro-rata accelerated non-renounceable entitlement offer, launched on December 4, 2023.

Mesoblast (ASX:MSB) gains FDA approval to fast-track Revascor in end-stage heart failure

Mesoblast (ASX:MSB) has received U.S. FDA approval to accelerate rexlemestrocel-L (Revascor) for patients with end-stage ischemic heart failure and reduced ejection fraction (HFrEF) with a left ventricular assist device (LVAD).

US FDA grants Mesoblast orphan-drug designation for Revascor

Mesoblast (ASX:MSB) has been granted ODD and RPDD from the United States FDA for its allogeneic cell therapy, Revascor.

Buyers (Bids)

Sellers (Offers)

Top Stories

Featured News